Exenatide sensitizes insulin-mediated whole-body glucose disposal and promotes uptake of exogenous glucose by the liver.
about
Portal glucose infusion-glucose clamp measures hepatic influence on postprandial systemic glucose appearance as well as whole body glucose disposal.Exendin-4 improves blood glucose control in both young and aging normal non-diabetic mice, possible contribution of beta cell independent effects.Glucagon-like peptide-1 receptor knockout mice are protected from high-fat diet-induced insulin resistanceHepatic portal vein denervation impairs oral glucose tolerance but not exenatide's effect on glycemia.Extracts from Salvia-Nelumbinis naturalis alleviate hepatosteatosis via improving hepatic insulin sensitivity.Pharmacokinetic and pharmacodynamic modeling of exendin-4 in type 2 diabetic Goto-Kakizaki rats.Exenatide Treatment Alone Improves β-Cell Function in a Canine Model of Pre-DiabetesEffects of intraportal exenatide on hepatic glucose metabolism in the conscious dog.Incretin-based therapies.Exendin-4 inhibits iNOS expression at the protein level in LPS-stimulated Raw264.7 macrophage by the activation of cAMP/PKA pathway.GLP-1 Receptor Agonist and Non-Alcoholic Fatty Liver DiseaseThe GLP-1 analogue exenatide improves hepatic and muscle insulin sensitivity in diabetic rats: tracer studies in the basal state and during hyperinsulinemic-euglycemic clamp.Incretin concepts.Glucagon-like peptide-1 receptor agonist treatment prevents glucocorticoid-induced glucose intolerance and islet-cell dysfunction in humans.Glucagon receptor antagonist-mediated improvements in glycemic control are dependent on functional pancreatic GLP-1 receptor.
P2860
Q33655537-2356CC37-A0C5-493C-A913-F77DC83BC1BCQ33927198-1EC64790-404F-4CB3-9587-9183211D7FA3Q34157515-3D40F1CE-FFA7-425F-BB65-2F96B88EE8C8Q34355968-DA825F32-BC3E-44C8-A6EF-62F7B85C7CA3Q34571695-8F7E125A-BC28-43BF-AE47-E748075F463CQ34702329-266E6204-5DBA-4FDC-8BED-E7598E7F8B3EQ36072493-78328DF9-FB64-4A11-84C7-C97514E65CD1Q37051107-9A66F835-89C8-47DE-891D-6A0ECE0C887FQ37894864-7F87D2F3-9BFF-4FD2-BEA9-CBDFA7C818D6Q39253744-78AFA59B-DCD1-448A-A6D3-FDAF1F7AABA1Q41944168-A9807729-D487-494E-878D-059197C33F58Q42099874-28880010-BA39-46E2-81BC-40B8B255F62BQ42183050-9EB29109-A2DE-4332-A8EC-17705823EA21Q42576497-31D97F1C-26F7-4469-B8DB-D2A8E57D0B13Q42963582-EA710EEE-9206-4CFD-82BC-90A1EDE1F905
P2860
Exenatide sensitizes insulin-mediated whole-body glucose disposal and promotes uptake of exogenous glucose by the liver.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Exenatide sensitizes insulin-m ...... xogenous glucose by the liver.
@en
Exenatide sensitizes insulin-m ...... xogenous glucose by the liver.
@nl
type
label
Exenatide sensitizes insulin-m ...... xogenous glucose by the liver.
@en
Exenatide sensitizes insulin-m ...... xogenous glucose by the liver.
@nl
prefLabel
Exenatide sensitizes insulin-m ...... xogenous glucose by the liver.
@en
Exenatide sensitizes insulin-m ...... xogenous glucose by the liver.
@nl
P2093
P2860
P356
P1433
P1476
Exenatide sensitizes insulin-m ...... xogenous glucose by the liver.
@en
P2093
Darko Stefanovski
Richard N Bergman
Vahe Mooradian
Viorica Ionut
P2860
P304
P356
10.2337/DB08-0875
P407
P577
2008-11-14T00:00:00Z